Education
About Us
Working with TipRanks
Follow Us
BioCardia Inc (BCDA)
NASDAQ:BCDA
BCDA Stock Chart & Stats
Day’s Range― - ―
52-Week Range$1.63 - $4.66
Previous CloseN/A
Volume12.78K
Average Volume (3M)462.20K
Market Cap
$10.85M
Enterprise Value$9.63M
Total Cash (Recent Filing)$980.00K
Total Debt (Recent Filing)$745.00K
Price to Earnings (P/E)―
Beta2.14
Next Earnings
Nov 05, 2025EPS Estimate
-0.21Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.40
Shares Outstanding5,801,224
10 Day Avg. Volume95,535
30 Day Avg. Volume462,196
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market Cap0.89
Enterprise Value/Revenue166.06
Enterprise Value/Gross Profit-22.35
Enterprise Value/Ebitda-1.11
Forecast
1Y Price Target
$2.00Price Target Upside10.50% Upside
Rating ConsensusHold
Number of Analyst Covering0
Bulls Say, Bears Say
Bulls Say
Financial PerformanceBiocardia announced financial results with an EPS better than the analyst's estimate, indicating better-than-expected financial performance.
Financial StabilityThe company has enough cash to fund ongoing operations through the first quarter of 2025, providing financial stability in the near term.
New ProductMorph DNA Introducer now commercially available, providing new revenue stream.
Bears Say
Clinical TrialDSMB determined that the study would not meet the primary Finkelstein Schoenfeld composite endpoint and recommended to pause enrollment.
Regulatory ChallengesPMDA willing to review CardiAMP HF data ahead of submission for approval in Japan.
BioCardia News
BCDA FAQ
What was BioCardia Inc’s price range in the past 12 months?
BioCardia Inc lowest stock price was $1.63 and its highest was $4.66 in the past 12 months.
What is BioCardia Inc’s market cap?
BioCardia Inc’s market cap is $10.85M.
When is BioCardia Inc’s upcoming earnings report date?
BioCardia Inc’s upcoming earnings report date is Nov 05, 2025 which is in 75 days.
How were BioCardia Inc’s earnings last quarter?
BioCardia Inc released its earnings results on Aug 11, 2025. The company reported -$0.4 earnings per share for the quarter, beating the consensus estimate of -$0.5 by $0.1.
Is BioCardia Inc overvalued?
According to Wall Street analysts BioCardia Inc’s price is currently Undervalued.
Does BioCardia Inc pay dividends?
BioCardia Inc does not currently pay dividends.
What is BioCardia Inc’s EPS estimate?
BioCardia Inc’s EPS estimate is -0.21.
How many shares outstanding does BioCardia Inc have?
BioCardia Inc has 5,801,224 shares outstanding.
What happened to BioCardia Inc’s price movement after its last earnings report?
BioCardia Inc reported an EPS of -$0.4 in its last earnings report, beating expectations of -$0.5. Following the earnings report the stock price went down -6.145%.
Which hedge fund is a major shareholder of BioCardia Inc?
Currently, no hedge funds are holding shares in BCDA
Company Description
BioCardia Inc
BioCardia, Inc., a clinical-stage regenerative medicine company, develops cellular and cell-derived therapeutics for cardiovascular and pulmonary diseases. Its lead therapeutic candidate is the CardiAMP Cell Therapy System for the treatment of heart failure and chronic myocardial ischemia; and allogeneic cell therapy for cardiac and pulmonary disease. The company is also developing allogeneic cells therapeutic platform, an investigational culture expanded bone marrow derived mesenchymal cell therapy, which is in Phase I/II trial for the treatment of ischemic systolic heart failure. In addition, it offers the Helix biotherapeutic delivery system that delivers therapeutics into the heart muscle with a penetrating helical needle from within the heart; and Morph deflectable guides and sheaths. The company is based in Sunnyvale, California.
BCDA Earnings Call
Q2 2025
0:00 / 0:00
Earnings Call Sentiment|Neutral
The earnings call highlighted significant progress in clinical trials and regulatory pathways, particularly in Japan, with promising partnership discussions. However, increased R&D expenses, a rise in net loss, and low cash reserves present challenges. The sentiment is cautiously optimistic with a focus on regulatory approvals and strategic partnerships.View all BCDA earnings summariesTechnical Analysis
Portage Biotech Inc
―
―
BioRestorative Therapies
―
Lyra Therapeutics
―
Bolt Biotherapeutics
―
Ownership Overview
18.66% Insiders
0.77% Mutual Funds
2.26% Other Institutional Investors
78.10% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---